Phase III clinical trials of GLP-1 receptor agonists in early Alzheimer's disease confirm substantial reductions in microglial neuroinflammation and neurofibrillary tangle progression despite modest primary cognitive score deltas, establishing neuroprotective metabolic activity in the brain. science.org